Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iain Gardner

Showing results (51-60 of 106) with videos related to

Pageof 11
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|June 10, 2026
Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions With the Antibody-Drug Conjugate Trastuzumab DeruxtecanAkiko Watanabe, Katherine L Gill, Kuan-Fu Chen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 7, 2020
A Laboratory-Specific Scaling Factor to Predict the In Vivo Human Clearance of Aldehyde Oxidase SubstratesMailys De Sousa Mendes, Alexandra L Orton, Helen E Humphries, et al.
International Journal of Molecular Sciences|September 13, 2025
Testing Strategies for Metabolite-Mediated NeurotoxicityJulian Suess, Moritz Reinmoeller, Viktoria Magel, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 8, 2021
Development of physiologically-based pharmacokinetic models for standard of care and newer tuberculosis drugsHelen Humphries, Lisa Almond, Alexander Berg, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 4, 2010
Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteersManoli Vourvahis, Michelle Gleave, Angus N R Nedderman, et al.
The AAPS Journal|March 20, 2019
Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic PopulationsKrishna K Machavaram, Chihiro Endo-Tsukude, Kimio Terao, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 26, 2024
Response to "Acetaminophen should be a critical reference hepatotoxin for evaluating human-relevant in vitro models"Lucia A Livoti, Rowena Sison-Young, Dennis Reddyhoff, et al.
The AAPS Journal|November 4, 2025
Investigating Sulfotransferase Mediated Drug Interactions of Ethinylestradiol using a Physiologically Based Pharmacokinetic ModelHarry P Moore, Kuan-Fu Chen, Aki T Heikkinen, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 21, 2022
Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp SimulatorPeter J Kilford, Kuan-Fu Chen, Kim Crewe, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|November 7, 2024
Limitations of acetaminophen as a reference hepatotoxin for the evaluation of in vitro liver modelsLucia A Livoti, Rowena Sison-Young, Dennis Reddyhoff, et al.
Pageof 11

Showing results (51-60 of 106) with videos related to

Sort By:
Pageof 11
CPT: Pharmacometrics & Systems Pharmacology|June 10, 2026
Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions With the Antibody-Drug Conjugate Trastuzumab DeruxtecanAkiko Watanabe, Katherine L Gill, Kuan-Fu Chen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 7, 2020
A Laboratory-Specific Scaling Factor to Predict the In Vivo Human Clearance of Aldehyde Oxidase SubstratesMailys De Sousa Mendes, Alexandra L Orton, Helen E Humphries, et al.
International Journal of Molecular Sciences|September 13, 2025
Testing Strategies for Metabolite-Mediated NeurotoxicityJulian Suess, Moritz Reinmoeller, Viktoria Magel, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 8, 2021
Development of physiologically-based pharmacokinetic models for standard of care and newer tuberculosis drugsHelen Humphries, Lisa Almond, Alexander Berg, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 4, 2010
Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteersManoli Vourvahis, Michelle Gleave, Angus N R Nedderman, et al.
The AAPS Journal|March 20, 2019
Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic PopulationsKrishna K Machavaram, Chihiro Endo-Tsukude, Kimio Terao, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 26, 2024
Response to "Acetaminophen should be a critical reference hepatotoxin for evaluating human-relevant in vitro models"Lucia A Livoti, Rowena Sison-Young, Dennis Reddyhoff, et al.
The AAPS Journal|November 4, 2025
Investigating Sulfotransferase Mediated Drug Interactions of Ethinylestradiol using a Physiologically Based Pharmacokinetic ModelHarry P Moore, Kuan-Fu Chen, Aki T Heikkinen, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 21, 2022
Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp SimulatorPeter J Kilford, Kuan-Fu Chen, Kim Crewe, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|November 7, 2024
Limitations of acetaminophen as a reference hepatotoxin for the evaluation of in vitro liver modelsLucia A Livoti, Rowena Sison-Young, Dennis Reddyhoff, et al.
Pageof 11